Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.54
- Piotroski Score 2.00
- Grade Buy
- Symbol (CING)
- Company Cingulate Inc.
- Price $4.79
- Changes Percentage (3.06%)
- Change $0.14
- Day Low $4.46
- Day High $4.86
- Year High $152.40
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/07/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$19.52
- Trailing P/E Ratio -0.04
- Forward P/E Ratio -0.04
- P/E Growth -0.04
- Net Income $-23,534,947
Income Statement
Quarterly
Annual
Latest News of CING
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Clonazepam, popular anxiety-reducing drug, recalled nationwide for 'possibly life-threatening' error
Inspirational speaker Frank Rodriguez warns about the future of Kensington, Philadelphia, following a city cleanup effort. Clonazepam recall due to mislabeling by Endo Inc. poses life-threatening risk...
By Fox News | 15 hours ago -
NASCAR: 23XI Racing And FRM Make Injunction Request U-Turn
23XI Racing and Front Row Motorsports have withdrawn their appeal for a preliminary injunction against NASCAR, following the removal of anticompetitive language in the Open Agreement. Both teams aim t...
By Newsweek | 1 day ago -
No. 25 Washington State facing Oregon State for de facto Pac-12 regular-season title
Sign up for AP Top 25 Poll Alerts to receive the latest updates. In a unique Pac-12 season, Oregon State and Washington State will clash for the league's regular-season title. Despite recent struggles...
By AP NEWS | 1 day ago
